BEIJING, Nov. 28 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA),
a leading provider of biopharmaceutical products in China, issues a corporate
update today.
Sales and Marketing
The unaudited sales of third quarter 2006, second quarter 2006, and third
quarter 2005 were RMB 35,975,000 or USD$4,510,000, RMB 23,908,000 or
USD$2,980,000, and RMB 16,198,000 or USD$1,987,000, respectively. Third
quarter 2006 sales increased 50% over second quarter 2006 and 122% over third
quarter 2005. The third quarter 2006 sales results are based on preliminary
unaudited financials and the Company has filed its financial results in the
semi-annual report of 2006 on Form 6K with the Securities and Exchange
Commission.
The sales of Anflu started in September 2006. An after-sales clinical
trial of Anflu was recently conducted in the City of Tianjin. A total 225
healthy adults and elders were vaccinated with Anflu. The result shows the
vaccine is well tolerated.
Update on Panflu Clinical Trial
Sinovac was approved by China State Food And Drug Administration (SFDA)
to give the third shot to those who were vaccinated with Panflu in Phase I
clinical trial. The trial will further demonstrate the tolerance of the
vaccine and immune response after a booster. It will also help on the
determination on the relevant dosage with different vaccination schedule. The
trial will be initiated shortly.
Sinovac has filed the application with China State Food And Drug
Administration for the application to conduct a Phase II human clinical trial
on its Pandemic Influenza (H5N1) vaccine. Sinovac has been granted fast track
status for the application of pandemic flu vaccine.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac’s vaccines
include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B)
and Anflu(TM) (influenza). Sinovac is currently developing human vaccines
against the H5N1 strain of pandemic influenza, Japanese encephalitis and
SARS. Additional information about Sinovac is available on its website,
http://www.sinovac.com . To be added to our distribution list, please email:
info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such
as "will," "expects," "anticipates," "future," "intends," "plans," "believes,"
"estimates" and similar statements. Among other things, the business outlook
and quotations from management in this press release contain forward-looking
statements. Statements that are not historical facts, including statements
about Sinovac’s beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. A number
of important factors could cause actual results to differ materially from
those contained in any forward-looking statement. Sinovac does not undertake
any obligation to update any forward-looking statement, except as required
under applicable law.
